Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two antigenic systems of the woodchuck hepatitis virus have been identified. The relationship between viral antigens of the woodchuck hepatitis virus and the human hepatitis B virus was determined by using immunoprecipitation, hemagglutination, and immune electron microscopy techniques. Antigens found on the cores of the two viruses were cross-reactive. Lack of cross-reactivity between the surface antigens of the two viruses in immunodiffusion experiments suggested that the major antigenic determinants of the viral surfaces are different; however, results of passive hemagglutination tests indicated that there are common minor determinants. Nucleic acid homology, as measured by liquid hybridization, was found to be 3 to 5% of the viral genomes. The results of this study provide further evidence that woodchuck hepatitis virus is the second member of a new class of viruses represented by human hepatitis B virus. Since virus-infected woodchucks may acquire chronic hepatitis and hepatocellular carcinoma, these antigens and their respective antibodies will be useful markers for following the course of virus infection in investigations of the oncogenic potential of this class of viruses. The nucleocapsid antigen described may be a class-specific antigen of these viruses and, thus, may be useful in discovering new members of the group.
 ...
PMID:Serological relationship of woodchuck hepatitis virus to human hepatitis B virus. 9 59

Patients with positive serum HBAg reactions were treated with Viramid (1-beta-D-ribofuranozyl-1, 2, 4-triazol-3-carboxamide) a new anti-viral drug. Of the patients involved in this study, 5 had chronic hepatitis or prolonged hepatitis and 12 were healthy HBAg carriers. Results obtained suggest that the drug had some action on serum HBAg titres with a decrease or negativation of HBAg serum titres in peripheric blood, the evaluation of which was immediately seen by employing the counterimmune electrophoresis technique.
 ...
PMID:[Action of an anti-viral on the Australia antigen in patients with hepatitis A virus and in healthy carriers]. 9 22

The concept of chronic hepatitis is very complex. There is no generally recognized definition and no agreement on the nomenclature. In more recent times a subdivision into chronic persisting (CPH) and chronic active (aggressive or progressive) hepatitis (cah) has been proposed. Morphologically CPH has a mononuclear inflammatory infiltration of the portal fields with preservation of the lobules. In positive hepatitis B CPH, orcein-positive milkglass-shaped hepatocytes and washed-out nuclei have recently been established by immunofluorescence. Periportal inflammation (piecemeal necrosis) is characteristic of CAH. Severe forms show hepatocytolysis and confluent necroses in addition. Since there is not always a sharp division between CPH and CAH, an unequivocal diagnosis of clinical, biochemical, serologic and immunological data is required.
 ...
PMID:[The morphogenesis of chronic hepatitis]. 10 39

The determination of enzyme activity in serum for the diagnosis of chronic hepatitis has become increasingly popular. According to the author's experience serum aminotransferase is raised in about 100% of cases of chronic active hepatitis and also in active cirrhosis, but in only about 70--80% of persisting hepatitis or in moderately active chronic hepatitis. They are frequently normal in inactive cirrhosis. After aminotransferases the alkaline phosphatase is of great importance for the differential diagnosis of icterus. If aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase are determined at the same time, every cholestatic icterus can be diagnosed with certainty.
 ...
PMID:[Clinical enzyme diagnosis in chronic hepatitis. Possibilities and limitations (author's transl)]. 10 40

The HBeAg-HBeAb system has been studied by means of the microimmunodiffusion technique on agar in patients suffering from acute hepatitis at various stages of the disease, in patients with chronic liver diseases and in asymptomatic carriers of HBsAg. The results correlate the presence of HBeAg with the state of the disease (initial phase of acute or chronic hepatitis) and the presence of HBeAb with clinical cure of an acute hepatitis or with the condition of healthy carrier. It is a personal impression also that an HBsAg + hepatitis can be cured more rapidly the better the immune response expressed by the appearance of HBeAb, and that a lacking or deficient immune response to HBeAg may underlie the chronic course of the disease. Emphasis is also laid on the early disappearance of HBeAb in patients with acute hepatitis, this being matched by its persistence in asymptomatic carriers of HBsAg. In this regard, the first results reported here on the identification of the immune globulin class to which the HBeAb belongs would appear to confirm the hypothesis that the anti-e response is of IgM type in acute hepatitis and of IgG type in HBsAg carriers.
 ...
PMID:[Further observations on the HBeAg-HBeAb system in the course of hepatitis and in HBsAg carriers]. 10 36

Liver dysfunction was observed in 33% of patients treated by hemodialysis and kidney transplantation. Fifty-eight percent of these cases of hepatitis occurred in patients with past or present HBs antigenemia, and 77% of HBsAg-positive patients showed evidence of LD. However, during the course of a program conducted from 1969 to 1976 and involving 267 patients, the decrease in the prevalence of HBs antigenemia observed during the last two years did not lead to any reduction in LD incidence. In a small number of patients, potentially hepatotoxic drugs could be incriminated, but in our experience azathioprine never appeared to be involved. In a few patients, LD was due to granulomatous disease of the liver, such as tuberculosis and schistosomiasis. Twenty-one (7%) of the 267 patients at risk developed chronic hepatitis, which contributed to death in nine patients. In 12 cases (three deaths), this form of hepatitis occurred in HBsAg-positive patients, and in nine cases (six deaths), in HBsAg-negative patients. In three of these latter individuals, cytomegalovirus could be incriminated. Routine monthly screening for CMV in kidney recipients confirmed the high incidence of this viral infection in such patients. Studies on murine CMV infection have demonstrated that this infection can be enhanced by histoincompatible graft or by cyclophosphamide in a model that is very close to the kidney recipient. As in mice, CMV infection in kidney recipients apparently results from reactivation of a latent infection. It seems to play a major role in the LD observed and could apparently lead to chronic hepatitis and even to cirrhosis of the liver. Finally, the occurrence of LD in HBsAg-, anti-HBs- and antiCMV-negative patients would suggest the responsibility of other viruses for the pathogenesis of liver disease in patients treated by hemodialysis and kidney transplantation. Besides Epstein-Barr virus, other viruses, such as hepatitis C virus, should be thoroughly scrutinized.
 ...
PMID:Liver disease in patients undergoing hemodialysis and kidney transplantation. 11 44

This paper describes a "solid-phase"-radioimmunoassay for the demonstration of HBeAg and anti-HBe. The investigations revealed the following results: 1. HBeAg is positive in all patients with acute type B-hepatitis during the acute phase of illness. During the normal course of the disease HBeAg turns to negative followed by an anti-HBe lasting for several months. 2. Cases with a persistent virus B-replication as HBsAg-positive CPH, CAH or patients on hemodialysis are positive for HBeAg in their serum. By means of the fluorescent antibody technique these patients have demonstrable HBcAg and HBeAg in their liver biopsies. 3. Healthy HBsAg carriers are anti-HBe-positive in their serum. In their liver biopsies there are no signs of an on-going virus B-replication (HBsAg and HBeAg negative). 4. The radioimmunological determination of HBeAg and anti-HBe enables us to differentiate between the groups with HBsAg positive acute or chronic hepatitis and the group of healthy HBsAg-carriers.
 ...
PMID:[Radioimmunological determination of HBeAg/anti-HBe in HBsAg-positive liver diseases and in "healthy" HBsAg carriers]. 11 95

Sera of 480 hospitalized hepatitis patients were tested for hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs) and to hepatitis B core antigen (anti-HBc), antibody to hepatitis A virus (anti-HAV) and anti-HAV of IgM-class. Serological markers indicating hepatitis A infection were found in 107 (22.3%) and markers indicating hepatitis B in 297 patients (61.9%), while 63 patients (13.1%) were classified as hepatitis type "non-A, non-B". The latter group mainly comprised drug addicts (50.8%), cases of post-transfusion hepatitis (11.1%) and patients without obvious hepatitis exposure (28.6%). In spite of these epidemiological similarities to hepatitis B, the maximum levels of serum alanine aminotransferase and bilirubin were comparable to those in patients with hepatitis A and significantly lower than in hepatitis B infection. Chronic hepatitis developed in 7.1% of the "non-A, non-B" patients, a figure close to that reported for hepatitis B.
 ...
PMID:Clinical, epidemiological and prognostic aspects of hepatitis "non-A, non-B"--a comparison with hepatitis A and B. 11 11

On liver biopsies of 20 children with different forms of chronic HBsAg-positive hepatitis, submitted to immunodepressive treatment, the presence and the distribution of core and delta antigens and their correlation with the different clinical forms have been studied with the direct immunofluorescence technique. Core antigen was present in 11 patients, delta antigen in 4 patients: both antigens in 3 cases. The percent rate of positive nuclei varied from 5 to 80%. All subjects negative for both antigens showed a favourable course. Delta antigen seems to be associated to forms with unsatisfactory course notwithstanding therapy, particularly to relapses and recurrences of chronic hepatitis in such a way as to hypothesize the possible responsibility either of another hepatitic virus (non A, non B virus) or of a different virus. Core morphological expression frequent in chronic hepatitis submitted to immunodepressive treatment, corresponded approximately to the finding thus far reported for the adults. The interpretation of these results, though difficult, shows remarkable interest for the pathogenetic and therapeutic considerations which follow.
 ...
PMID:[Research on the core and delta antigens of human hepatitis virus B using immunofluorescence, with liver biopsy of pediatric subjects affected by various forms of chronic hepatitis]. 12 13

Purified and concentrated preparations of Australia antigen had no stimulating effect on leukocytes of human subjects under study when tested either on DNA-polymerase activity, 3H-thymidine uptake or chromosomal alterations. Moreover, in patients with chronic hepatitis and cirrhosis of the liver no correlation between antigenemia and chromosome aberrations in blood leukocyte cultures could be detected. On the other hand, a serum obtained from a virus hepatitis patient with Australia antigen in the blood was found to stimulate leukocyte cultures from one patient with Down's syndrome and antigenemia, one mentally retarded patient and three normal donors. This stimulating agent is obviously not associated with Australia antigen.
 ...
PMID:Investigation of the nature of Australia antigen. I: The absence of biological activity of Australia antigen in human blood leukocyte culture. 12 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>